How Does Myrbetriq Work? Mechanism of Action Explained in Plain English

Myrbetriq (mirabegron) is described as a "beta-3 adrenergic agonist" — which tells a pharmacologist everything and most patients nothing. This article breaks down exactly what that means, how it translates into relief for overactive bladder symptoms, and why this mechanism matters compared to older OAB treatments.

First: What Happens in an Overactive Bladder?

To understand how Myrbetriq works, it helps to understand what's going wrong in overactive bladder. Normally, the bladder fills gradually with urine over hours. As it fills, the detrusor muscle (the wall of the bladder) remains relaxed, allowing it to expand like a balloon. When the bladder is full enough, signals from your nervous system tell you it's time to go — and only then does the detrusor muscle contract to empty the bladder.

In overactive bladder, inappropriate signals cause the detrusor muscle to contract before the bladder is full. The result: sudden, strong urges to urinate — often when you're nowhere near a bathroom. These contractions can also cause leakage if they're strong enough before you can get to a toilet. The cycle is uncomfortable, disruptive, and often embarrassing.

How the Old OAB Drugs Work (Anticholinergics)

Before Myrbetriq, the main pharmacological approach to OAB was anticholinergic drugs (oxybutynin, tolterodine, solifenacin, etc.). These work by blocking muscarinic receptors on the detrusor muscle, preventing the nerve signals that trigger premature contractions.

The problem: muscarinic receptors aren't just in the bladder. They're in the salivary glands, gut, eye, and brain. Blocking them throughout the body creates a predictable cascade of side effects: dry mouth (blocked salivary glands), constipation (slowed gut motility), blurred vision (pupil effects), and in older adults, cognitive problems (crossing the blood-brain barrier).

How Myrbetriq Works Differently: Beta-3 Adrenergic Agonism

Myrbetriq takes an entirely different approach. Rather than blocking nerve signals, it works with a different receptor system in the bladder. The bladder wall is rich with beta-3 adrenergic receptors. When these receptors are stimulated, they cause the detrusor muscle to relax.

Myrbetriq is an agonist — it activates these beta-3 receptors. By selectively stimulating beta-3 adrenergic receptors in the detrusor muscle, Myrbetriq:

• Promotes muscle relaxation during the bladder filling phase
• Increases bladder capacity — the bladder can hold more urine before triggering urgency
• Reduces the frequency of those unwanted premature contractions
• Does not interfere with normal bladder emptying — the void reflex itself is preserved

Why Doesn't Myrbetriq Cause Dry Mouth and Constipation?

Because beta-3 adrenergic receptors are predominantly expressed in the bladder (and also in fat tissue and heart), Myrbetriq's effects are much more targeted than anticholinergics. The salivary glands, gut, and brain don't have significant beta-3 receptor populations, so stimulating these receptors doesn't produce the body-wide side effects that make anticholinergics so difficult for many patients to tolerate.

This is particularly meaningful for older adults, where anticholinergic burden from multiple drugs is associated with increased risk of cognitive decline and falls. Myrbetriq provides an effective OAB treatment without adding to that burden.

Why Does Myrbetriq Affect Blood Pressure?

Beta-3 adrenergic receptors are also found in blood vessels and the heart. When stimulated, they can cause a small degree of vasodilation (blood vessel relaxation) but also have effects on heart rate and cardiac function in some patients. This is why Myrbetriq can cause modest blood pressure increases and occasionally tachycardia. The effect on blood pressure in adult OAB trials was small (approximately 0.5-1 mm Hg above placebo), but it's why blood pressure monitoring is recommended, especially at the start of therapy.

What About the Extended-Release Formulation?

Myrbetriq is designed as an extended-release tablet — the active drug is released gradually over 24 hours rather than all at once. This is why you take it just once daily, and why you must swallow it whole (crushing or breaking it would release the drug too quickly, altering the pharmacokinetic profile and potentially increasing side effects). The extended-release design provides steady, consistent drug levels throughout the day.

How Does Myrbetriq Compare to Gemtesa (Vibegron)?

Vibegron (Gemtesa) is the other FDA-approved beta-3 adrenergic agonist for OAB. Both mirabegron and vibegron work via the same receptor mechanism — beta-3 adrenergic agonism. Head-to-head studies suggest comparable efficacy. Key differences: vibegron is taken as a single 75 mg tablet (one dose fits all) versus Myrbetriq's adjustable 25-50 mg range; vibegron has a somewhat more selective beta-3 binding profile that may result in slightly lower cardiovascular effects in some patients. Vibegron is brand-only as of 2026.

Also see What Is Myrbetriq? and Myrbetriq Side Effects for related guides.